Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.
NCT00077987
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Metastatic colorectal cancer
- Failed selected cancer therapies in the past.
- Prior treatment with tyrosine kinase inhibitors or VEGF inhibitors other than
bevacizumab.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Mobile, Alabama
- Tucson, Arizona
- Fresno, California
- Stamford, Connecticut
- Washington, District of Columbia
- Jacksonville, Florida
- New Port Richey, Florida
- Tamarac, Florida
- Rockford, Illinois
- Terre Haute, Indiana
- New Orleans, Louisiana
- Annapolis, Maryland
- Pittsfield, Massachusetts
- Minneapolis, Minnesota
- Columbia, Missouri
- Billings, Montana
- Las Vegas, Nevada
- Hooksett, New Hampshire
- Lebanon, New Hampshire
- Rockville Centre, New York
- Greenville, North Carolina
- Hendersonville, North Carolina
- Hickory, North Carolina
- Winston - Salem, North Carolina
- Zanesville, Ohio
- Charleston, South Carolina
- Temple, Texas
- Newport News, Virginia
- Milwaukee, Wisconsin
- Halifax, Nova Scotia
- Kingston, Ontario
- Kitchener, Ontario
- Windsor, Ontario
- Fleurimont, Quebec
- Kashiwa, Chiba
- Suntougun, Shizuoka
- Chuo-ku, Tokyo
- Poway, California
- Washington, District of Columbia
- Tampa, Florida
- New York, New York
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments. | |||
Official Title ICMJE | A Phase II Study Of SU011248 In Patients With Metastatic Colorectal Cancer Who Have Previously Failed Treatment With Irinotecan, Oxaliplatin, And A Fluoropyrimidine, With And Without Bevacizumab | |||
Brief Summary | Assessment of safety and efficacy of SU11248 in patients with metastatic colorectal cancer who have failed selected previous treatments. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Colorectal Neoplasms | |||
Intervention ICMJE | Drug: SU011248 | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | 84 | |||
Original Enrollment ICMJE | Not Provided | |||
Study Completion Date ICMJE | April 2005 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Not Provided | |||
Removed Location Countries | United States | |||
Administrative Information | ||||
NCT Number ICMJE | NCT00077987 | |||
Other Study ID Numbers ICMJE | A6181003 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Not Provided | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | October 2005 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |